NASDAQ:DFFN - Diffusion Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $3.50
  • Forecasted Upside: 400.00 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.70
▼ -0.03 (-4.11%)
1 month | 3 months | 12 months
Get New Diffusion Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DFFN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DFFN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$3.50
▲ +400.00% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Diffusion Pharmaceuticals in the last 3 months. The average price target is $3.50, with a high forecast of $3.50 and a low forecast of $3.50. The average price target represents a 400.00% upside from the last price of $0.70.
Hold
The current consensus among 1 investment analysts is to hold stock in Diffusion Pharmaceuticals. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/4/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/2/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/1/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/25/2020

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/17/2020HC WainwrightDowngradeBuy ➝ NeutralHigh
i
Rating by S. Ramakanth at HC Wainwright
8/12/2020HC WainwrightReiterated RatingBuy$3.50High
i
Rating by Swayampakula Ramakanth at HC Wainwright
3/19/2020HC WainwrightReiterated RatingBuy$3.50High
i
Rating by Swayampakula Ramakanth at HC Wainwright
12/18/2019HC WainwrightLower Price TargetBuy$10.00 ➝ $3.50Medium
i
3/20/2019HC WainwrightBoost Price TargetBuy$10.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
11/15/2018HC WainwrightSet Price TargetBuy$15.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
8/20/2018HC WainwrightReiterated RatingBuy$18.75Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
4/16/2018HC WainwrightSet Price TargetBuy$15.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
3/21/2018HC WainwrightInitiated CoverageBuy ➝ Buy$18.75High
i
Rating by S. Ramakanth at HC Wainwright
(Data available from 11/25/2015 forward)
Diffusion Pharmaceuticals logo
Diffusion Pharmaceuticals Inc., a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of metastatic brain cancer; and Phase II trial for the treatment of acute stroke. The company is also developing RES-529, a PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. has a cooperative research agreement with the University of Virginia Health and the Integrated Translational Research Institute of Virginia to evaluate the transcrocetinate sodium in patients with acute respiratory distress syndrome associated with COVID-19 infection. The company was founded in 2001 and is headquartered in Charlottesville, Virginia.
Read More

Today's Range

Now: $0.70
$0.69
$0.76

50 Day Range

MA: $0.81
$0.63
$0.93

52 Week Range

Now: $0.70
$0.25
$1.60

Volume

1,042,520 shs

Average Volume

3,797,439 shs

Market Capitalization

$44.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.51